for quarter joining Ping. second conference you you and Dyadic’s thank Thank Hello, everyone, call. XXXX
for government in the continues continued speed efficiency for garner and recognition quarter XXXX internationally praise its We've of as our in seen to academia, CX agencies. technology the momentum first and the and industry, U.S. and
markets. significant platform has traction and alternative both In protein in addition, our the gained Dapibus bioindustrial
We're significant of new business research the year. long-term growth with and excited core about across I growth continue this advances and first We revenues On months ongoing future Rubic, six of successes prospects for and Februaryabic, XX.X% are each will development revenue call, our our to highlight today's and collaborations year-over-year and of technological and recent and Janssen, achieve for the we current the markets. our others. have Joe delivering strong continuing multiple collaborations while
positive monoclonal continue pathologies, memorandum anti-epidemic have Bangladesh. and of development I on public performs antibodies announced study, clinical enter state-owned in Bangladesh's the the the of the our for epidemic, into opportunities diseases prevention pharmaceutical with internal hub recently health projects Drugs in advancements functions phase Family Foundation, To research, and of first-in-human albumin vaccines programs and Siena, and our I with of development, theorem and which understandings biopharmaceutical improvement data recently under facilitate Welfare accelerated focus CGMP Limited partnerships, of the emerging, Health production, and production di Biotecnopolo of additional preclinical To Ministry two pandemic, announced the and from the Essential development treatment the particular and that Company control an Italian company for of government's to like and EDCL, also the a of collaborations Bangladesh.
both applying of traditional required speeding our our safe value pandemic that filament we quantities vaccines produce verticals develop to will monetization platforms, to CX costs is the and dietic cell with enzymes, production manufacture to core and to lead drugs, proteins currently fungal needs. effective the therapies biologic precipice and shareholder versus makes global the What intercollaborators. CX increase health care for protein and the used and of that other Dapibus, near of or lines antibodies, platform and unique unparalleled for believe each protein at are and we across microbial believe will We production significantly antigens, ability
health to used no or repeatedly more in XXX viruses productive CHO-cells, being significantly than which being baculovirus-insect And and than the and cell to also vaccines. times in at processing, are either to is versus up produce cells, quantities hamster animal used CX Chinese that lower vaccines shown times downstream the that We've shorter both ovary rapidly greater more CX is platform fermentation currently in enabling traditional be than release today. lines the removed costs need baculovirus of production recombinant and human
development These protein coupled awareness has our a and study our in for animal production with characteristics, the produced health. and in platform data from increased human the first human protein CX interest antigen, to recombinant CX and of in vaccine production led
of virus, HXNX Earlier Marburg our from multiple the Ebola bird variety vaccine for first CX a Nile Sudan recombinant globally booster candidates. virus, second for wide proteins CX and protein an flu, this influenza, We're trial and in platform. from human protein with to safety a The vaccine Poison, traction as trial produced receiving quarter, disease applications helping DYAI-XXX, on with virus, establish grant in such update RVFV, candidates, the collaboration provided as COVID-XX is platform the seasonal as record well production through scientists regulatory expand other for data this pandemic continuing candidate. we COVID-XX RBD submitted in U.S. phase West to infectious generation one of agencies
monoclonal the to third-party number produce independent [indiscernible] mAbs parties, assayed were To ensure and binding CX infectious or appropriate similarity as big activity proteins mAbs. and of CHO-produced external between neutralizing the which quality, report of biotech pharma disease can demonstrated a CX-produced monoclonal such academia, we've great antibodies with from assays multiple mAbs, therapeutic by to antibodies expressed a
antibody demonstrated with a in antibody was next in the monoclonal of CX-produced to COVID-XX observed these CHO-produced we comparator signs antibody-mediated The primate study. where enhancement no evaluating step animal nonhuman proteins comparability monoclonal studies, a that for
titled obtained SARS-CoV-X in a a and Filamentous primates. was several was to other and submitted Osterhaus studies XXXX, CX This safety Human authors. Dr. Antibody Albert journal monoclonal the cell-produced Hamster hamsters and nonhuman efficacy with results Fungus Models. collaboration antibody a and In scientific manuscript peer-reviewed manuscript Primate Nonhuman June done in Provides in The Produced, with Monoclonal Protection describes from
is have and standards they critical development. partners the potential as safety targets for must that to advancement. profile lines of for required produce quality regulatory data commercial our their the Data select cell clinical their forefront aid and to ensure This scientific products
are been antigens We as ability trials candidates on influenza, also complex proteins ferritin designing due such in nanoparticles. such and range and The Nanoparticle a been We've and pathogens Epstein-Barr to wide conjugating express diseases CX performing in better immunogenicity. vaccines to developed molecules. and increasing clinical against their as of focusing cells SARS-CoV-X. safety have have to now enhance interest ferritin-based
and to particle challenges. positioned of platform folding Manufacturing feel proper heterogeneity antigens, costs be productivity the CX uniquely we address that some challenges overcome to of fused and to is and still related need these
methods to We other and also durability are technologies new developing vaccine more to adjuvants. powerful improve efficacy targeting and increase
lasting range other such pandemic in trials. encephalitis diseases. Verovax, We domain. included and longer a with the partner, are to well in partners With several our system, ferritin a relevant and as and improved and are with testing These potential of more AMHC as antigens disease areas advancements evaluating as animal meningitis influenza Fluenza develop infectious antigen effective targeting that as new trimerization developed adjuvants and across COVID-XX, antigens as COVID-XX an and we Dyadic's well wide vaccines with enable nanoparticle CX-produced the
term COVID-XX continued They leading and affordably. and as positive using on in recent and products sustaining continues our potential results for the with companies longer partnerships which be well vaccine and Janssen to human the as partners of cGMP advancing continent pharmaceutical building India. strategic manufactured potential have CX Health commercial rapidly focus cells with Rubic-X animal in African Pharmaceuticals Omicron development to under larger the CX-expressed and production as with clinical We've antigens show such quantities health for Epygen more vaccines guidelines of
vaccines Dr. the experts vaccines of equipped R&D CX antibodies and vaccines research a treatment world's release, head at and leading globally most known an was a FBS the development, one served and of Novartis production prepared Understanding Memorandum for we scientist at study, GlaxoSmithKline, Repioli Repioli development Biotecnopolo clinical development, platform. and to and of Fondazione recently Vaccines epidemic company's Siena approval, to the pathologies. regulatory signed of we and announced perform press FBS is GSK. immunology. conduct to vaccine Prior foremost Dr. role development pandemic that hub is in of global using diagnostics Division FBS, of his the is emerging FBS. protein and with head monoclonal production anti-pandemic vaccines and chief commercialization Dr. vaccines or the led for Repioli. particular at focus in as by as research the today's the and in Reno and of work therapeutic manufacturing of proteins his external the on Vaccine FBS's is function for di with Furthermore,
parties developing ongoing also in developed CX, traditional are Discussions with potential several the interested and of countries.
week, cost, objectives health risk associated product of a across on on This the timeline is we and update decrease utilization this recombinant an and capability include our commercialization commercial to one on programs less trials. opportunities human pipeline whose our commercialization dependent expected is our with development. namely core provided albumin. focus and Earlier that proteins not human time, internal verticals, shorter-term development and refined improve We're projects, to these an clinical lengthy potential to internal Our proteins enzymes of opportunities. continuing to have with or potential, serum revenue, have
year approximate $X.X due product growing health. segment, tool at the billion a the R&D. disease, diagnostic increased but a in albumin of used use being only X% as albumin serum development is a it's an The In multitude common to for human treatment not currently vaccines global reagent markets over of a pharmaceutical market across in potential a market and serum animal and in as is developed
and pricing microbial and productive using animal-free has There at CX serum and to Dyadic across albumin platforms to low-cost price due media. produce of other Dapibus points grades many different competitive these are markets. the our potential albumin highly
this and U.S. pandemic patent claims our with company's and In generated, of the of being we application, Earlier and protein allowance Trademark whose vaccines year, for of received IP seasonal cover Dyadic a production CX Office clinical from data the addition robust to from manufacture state. are notice platform. Patent protecting development technology a the the
or patent allowance a scheduled, this flu, bird are animal antigens and animal influenza, we forefront trials earlier ongoing infectious carried vaccine last year additional more year development, than with comes for the half-dozen which with other is HXNX trials, for example, as CX-produced announce Dyadic timely of This diseases. that out and being at
need vaccines that with vaccine leading effective billion flu reported to the at XXXX, and by a approximately billion expected more is currently more vaccines. valued $X It and has for $XX influenza There's available multivalent over been the seasonal alone human global unmet market. to grow market
an are that fully we've interest core verticals. for the a similarities between on and in and our and science health, health as we There our animal targeting announcement attractive another expanded proteins, human scientific recognition, makes margin new antigen efforts segment in our needs generating [indiscernible] partner our livestock today's the animal human data, collaboration such started other global the and with for these and with The the health be its What supply Dyadic have not on CX a they're the collaboration increased advancements demonstrated as funded produced only market a of impact health, we sensitivity therapeutic platform. in and human in this project an to animal health verticals are leveraging many have and translating market accelerated can the significant animal potentially and across is are outbreak chain vaccines health. core
This infectious in is disease just to production global threats, and the can solution why platform not health. pandemic a emerging humans, also response, and animal we be believe but CX
production per year, that level we very As last for announced livestock disease. record can produce of we antigens a quantities of that infectious grams antigen, liter and antigen achieved demonstrating we'd XX platforms late mentioned large of a our
proteins, stockpiling. antigens, therapeutic potential In the and products made also be pandemic these rapidly can quantities preparedness of This CX, at for a addition means response of production to large cost. antibodies, or a low platform and
technical promise potential opportunity human area of not resource great of one is capability segment require significant dyadic terms does another or vertical and from third for believe and alternative also we holds yet which animal in requirements. excitement this in pursuits near-term and health of of departure Exploiting revenue. Our a terms proteins our
rapid non-pharmaceutical the proteins, designed low-cost further manufacture wellness. to is other large-scale metabolites, Dapibus market. and resources Dyadic enable rapidly a the fungal-based, within filamentous, to projects its growing and of customized is protein food, platform, launched for biologic continuing applications, for expression and as nutrition, development has production products use gene dedicate this microbial support future and Dapibus and existing platform. such Dyadic and and health, enzymes, in
One is area analytical expression of demand our Dapibus, platform. for positive or the the today commitment using enzyme of to casein foods protein that casein and transect protein-enriched casein non-pharmaceutical synthetic plastics, growth, applications focus as expected production announced market. within results fibers this dairy protein chemicals, proteins one This successful expansion. and for to market is drive global initial demonstrates market our segment driving the for Growing vertical. is of developing industrial than core use more commercial opportunities further such We
turn now Business Chief will to our development Joe? more trial call verticals. across business Joe I the to core our detailed our Phase progress update a efforts over Hazleton, our provide and on Officer, discuss I
